Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2a study is to establish safety and preliminary efficacy of
treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7
or TTN variants .